Myasthenia gravis, ravulizumab available in Italy
The drug is approved on a reimbursement basis for adult patients positive for anti-acetylcholine receptor antibodies The Italian Medicines Agency (AIFA) has approved the reimbursement of the drug ravulizumab for the treatment, in addition to standard therapy, of adult patients suffering from generalized myasthenia gravis (gMG) and positive for anti-acetylcholine receptor (AChR) antibodies. gMG is … Read more